ChemoCentryx to Present at Three Upcoming Investor Conferences
- Rodman & Renshaw 19th Annual
Global Investment Conference Monday, September 11, 2017at 3:50 p.m. Eastern Time Lotte New York Palace Hotel, New York, NY
- Ladenburg Thalmann 2017 Healthcare Conference
Tuesday, September 26, 2017at 10:30 a.m. Eastern Time Sofitel Hotel, New York, NY Cantor Fitzgerald2017 Global Healthcare Conference Wednesday, September 27, 2017at 2:15 p.m. Eastern Time InterContinental New York Barclay Hotel, New York, NY
Live audio webcasts of the presentations can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Replays of the webcasts will be available on the Company's website for two weeks following each live presentation.
Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR. Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). In clinical studies to date, avacopan was shown to be safe, well tolerated and provided effective control of the disease while allowing elimination of high-dose steroids, part of the current standard of care. Avacopan is also being developed in patients with C3 glomerulopathy (C3G) and
atypical hemolytic uremic syndrome (aHUS). The
The Company's other late stage drug candidate is CCX140, an inhibitor of the chemokine receptor known as CCR2, which is currently being developed for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease.
Susan M. KanayaExecutive Vice President, Finance and Chief Financial and Administrative Officer email@example.com Media: Stephanie Tomei408.234.1279 firstname.lastname@example.org Investors: Burns McClellan, Inc. Steve Klass212.213.0006 email@example.com
News Provided by Acquire Media